Guttman-Yassky E, Facheris P, Gomez-Arias PJ, Del Duca E, Da Rosa JC, Weidinger S, Bissonnette R, Armstrong AW, Seneschal J, Eyerich K, Estrada YD, Bose SN, Xu D, Chen A, Tatulych S, Güler E, Chan G, Page KM, Kerkmann U. Allergy. 2023 Dec 18. doi: 10.1111/all.15969. PMID: 38108208

Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.

Bissonnette R, DuBois J, Facheris P, Del Duca E, Kim M, Correa Da Rosa J, Trujillo DL, Bose S, Pagan AD, Wustrow D, Brockstedt DG, Wong B, Kassner PD, Jankicevic J, Ho W, Cheng LE, Guttman-Yassky E. Allergy. 2023 Nov 20. doi: 10.1111/all.15949. PMID: 37984453

Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.

Guttman-Yassky E, Del Duca E, Da Rosa JC, Bar J, Ezzedine K, Ye Z, He W, Hyde C, Hassan-Zahraee M, Yamaguchi Y, Peeva E. J Allergy Clin Immunol. 2024 Jan;153(1):161-172.e8. doi: 10.1016/j.jaci.2023.09.021. Epub 2023 Sep 28. PMID: 37777018

Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines.

Kim M, Renert-Yuval Y, Stepensky P, Even-Or E, Zaidman I, Fachler T, Neumark M, Zamir M, NandyMazumdar M, Gour D, Facheris P, Carroll B, Liu Y, Yu Ekey ML, Andrews E, Meariman M, Angelov M, Bose S, Estrada YD, Molho-Pessach V, Guttman-Yassky E. J Invest Dermatol. 2023 Sep 23:S0022-202X(23)02595-2. doi: 10.1016/j.jid.2023.08.026. Online ahead of print. PMID: 37742913

Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.

Renert-Yuval Y, Del Duca E, Arents B, Bissonnette R, Drucker AM, Flohr C, Guttman-Yassky E, Hijnen D, Kabashima K, Leshem YA, Paller AS, Silverberg JI, Simpson EL, Spuls P, Vestergaard C, Wollenberg A, Irvine AD, Thyssen JP. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):42-51. doi: 10.1111/jdv.19506. Epub 2023 Sep 21. PMID: 37700595

Alopecia Areata: Current Treatments and New Directions. 

Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22. PMID: 37606849

Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies.

Del Duca E, He H, Liu Y, Pagan AD, David E, Cheng J, Carroll B, Renert-Yuval Y, Bar J, Estrada YD, Maari C, Proulx ES, Krueger JG, Bissonnette R, Guttman-Yassky E. Allergy. 2024 Jan;79(1):80-92. doi: 10.1111/all.15845. Epub 2023 Aug 14. PMID: 37577841

Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.

Guttman-Yassky E, Facheris P, Da Rosa JC, Rothenberg-Lausell C, Del Duca E, David E, Estrada Y, Liu Y, Bose S, Chowdhury M, Munera C, Goncalves J, Nograles K, Kim BS, Lebwohl M. J Allergy Clin Immunol. 2023 Oct;152(4):916-926. doi: 10.1016/j.jaci.2023.06.023. Epub 2023 Jul 13. PMID: 37453614

CLA+ memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis. 

Nicolàs LSS, Czarnowicki T, Akdis M, Pujol RM, Lozano-Ojalvo D, Leung DYM, Guttman-Yassky E, Santamaria-Babí LF. Allergy. 2024 Jan;79(1):15-25. doi: 10.1111/all.15816. Epub 2023 Jul 13. PMID: 37439317

Atopic dermatitis induced during anti-TNF-α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab.

Pagan AD, Ghalili S, Cices A, Facheris P, Tan K, Ungar B, Guttman-Yassky E. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2235-2238.e1. doi: 10.1016/j.jaip.2023.03.054. Epub 2023 Apr 21. PMID: 37088378

Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin.

Kim M, Del Duca E, Cheng J, Carroll B, Facheris P, Estrada Y, Cha A, Werth J, Bissonnette R, Nocka K, Zang C, Pavel AB, Guttman-Yassky E. J Am Acad Dermatol. 2023 Aug;89(2):283-292. doi: 10.1016/j.jaad.2023.02.064. Epub 2023 Apr 11. PMID: 37054814

Age of onset defines two distinct profiles of atopic dermatitis in adults. 

Facheris P, Da Rosa JC, Pagan AD, Angelov M, Del Duca E, Rabinowitz G, Gómez-Arias PJ, Rothenberg-Lausell C, Estrada YD, Bose S, Chowdhury M, Shemer A, Pavel AB, Guttman-Yassky E. Allergy. 2023 Aug;78(8):2202-2214. doi: 10.1111/all.15741. Epub 2023 Apr 18. PMID: 37032461

Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.

Guttman-Yassky E, Bar J, Rothenberg-Lausell C, Eichenfield L, Grada A, Abuabara K, Chapman M, Calimlim B, Wegzyn C, Gamelli A, Krueger W, Munoz B, Knapp K, Faller R, Crawford J, Silverberg J. J Drugs Dermatol. 2023 Apr 1;22(4):344-354. doi: 10.36849/JDD.7473. PMID: 37026893

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.

Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. Cell Mol Immunol. 2023 May;20(5):448-474. doi: 10.1038/s41423-023-00992-4. Epub 2023 Mar 16. PMID: 36928371

Proteomic characterization of atopic dermatitis blood from infancy to adulthood. 

Del Duca E, Renert-Yuval Y, Pavel AB, Mikhaylov D, Wu J, Lefferdink R, Fang M, Sheth A, Blumstein A, Facheris P, Estrada YD, Rangel SM, Krueger JG, Paller AS, Guttman-Yassky E. J Am Acad Dermatol. 2023 May;88(5):1083-1093. doi: 10.1016/j.jaad.2022.12.050. Epub 2023 Feb 10. PMID: 36773824

Oral Janus kinase inhibitors for atopic dermatitis. 

Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Ann Allergy Asthma Immunol. 2023 May;130(5):577-592. doi: 10.1016/j.anai.2023.01.020. Epub 2023 Feb 1. PMID: 36736457

No association between dupilumab use and short-term cancer development in atopic dermatitis patients.

Owji S, Ungar B, Dubin DP, Poplausky D, Young JN, Ghalili S, Han J, Srinivasan D, Packer S, Pavel AB, Correa da Rosa J, Guttman-Yassky E, Gulati N. J Allergy Clin Immunol Pract. 2023 May;11(5):1548-1551. doi: 10.1016/j.jaip.2022.12.018. Epub 2022 Dec 26. PMID: 36581076 

Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome.

Kim M, Ungar B, Estrada Y, Pavel AB, Guttman-Yassky E. Ann Allergy Asthma Immunol. 2023 Mar;130(3):355-358. doi: 10.1016/j.anai.2022.12.006. Epub 2022 Dec 10. PMID: 36509406 

Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.

Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S, Gómez-Arias PJ, Angelov M, Bares J, Chima M, Estrada YD, Garcet S, Lebwohl MG, Krueger JG, Guttman-Yassky E. Allergy. 2023 Apr;78(4):1047-1059. doi: 10.1111/all.15561. Epub 2022 Nov 5. PMID: 36271804

The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients.

Ungar B, Hartzell S, Lozano-Ojalvo D, Ghalili S, Bose S, Golant AK, Tan K, Estrada YD, Singer GK, Pavel AB, Cravedi P, Guttman-Yassky E. Allergy. 2023 Feb;78(2):571-574. doi: 10.1111/all.15540. Epub 2022 Oct 17. PMID: 36181718

Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases.

Pavel AB, Del Duca E, Cheng J, Wu J, Ungar B, Estrada YD, Jack C, Maari C, Proulx ÉS, Ramirez-Valle F, Krueger JG, Bissonnette R, Guttman-Yassky E. Allergy. 2023 Jan;78(1):178-191. doi: 10.1111/all.15538. Epub 2022 Oct 8. PMID: 36178084